ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

EP: 2.Key Findings from the NADINA Trial at ASCO 2024

Now Viewing

EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

Video content above is prompted by the following:

• Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs nivolumab in patients with previously untreated metastatic or unresectable melanoma.
  • What was the objective of this study?
  • How was this study designed/what methodology was used?
  • What results were presented?
• Please provide your key takeaways from this study.
  • How might these findings impact the management of patients with metastatic melanoma?
• The study examined melanoma-specific survival (MSS) outcomes. What is the significance of sustained improvement in MSS observed with nivolumab plus relatlimab?